Six stories for HIV Vaccine Awareness Day
Click Here to Manage Email Alerts
Globally, more than 37 million people are living with HIV, nearly two-thirds of them in Africa.
Despite a decades-long effort, there is still no vaccine available to prevent HIV infection.
In conjunction with HIV Vaccine Awareness Day — an observance led by the National Institute of Allergy and Infectious Diseases — Moderna on Wednesday announced the start of a phase 1 clinical trial of an HIV messenger RNA vaccine candidate in Rwanda and South Africa.
To mark the day, we compiled a list of other recent stories showcasing HIV vaccine research.
After more than 40 years, ‘HIV vaccine remains elusive’
After more than 40 years, a vaccine against HIV “remains elusive” because of several significant barriers, including the complexity of the virus and shifts in focus to other infectious diseases, like COVID-19, an expert said. Read more.
HIV cure research: Trying to eliminate a virus that ‘hides out’
Scientists have also yet to find a cure for HIV. Healio spoke with experts about recent breakthroughs in research and promising advances in the ongoing effort to cure HIV. The story also touches on the development of HIV mRNA vaccines in the wake of the technology’s success during the COVID-19 pandemic. Read more.
Results of ‘truly disappointing’ HIV vaccine trial published
Researchers published data from a late-stage clinical trial of a once-promising HIV vaccine candidate more than a year after the trial was stopped early because the vaccine was not preventing infections. Read more.
For the first time, researchers say infusions of antibodies can prevent HIV infection
According to clinical trial results presented at the HIV Research for Prevention virtual meeting, infusions of a broadly neutralizing antibody called VRC01 were effective at preventing infection from HIV strains that were sensitive to the antibody, although the infusions offered no protection against unsusceptible strains. NIAID Director Anthony S. Fauci, MD, said insights from the trial could help lay the foundation for future vaccine development. Read more.
Experimental HIV vaccine does not protect women
Johnson & Johnson’s investigational HIV vaccine did not provide sufficient protection against HIV infection among women enrolled in the phase 2b Imbokodo trial in sub-Saharan Africa. Read more.
New clinical trial will test three mRNA vaccine candidates for HIV
The NIAID announced that it has initiated a phase 1 clinical trial of three experimental messenger RNA HIV vaccines — currently named BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA and BG505 MD39.3 gp151 CD4KO mRNA. Read more.
References:
IAVI and Moderna launch first-in-Africa clinical trial of mRNA vaccine development program. https://investors.modernatx.com/news/news-details/2022/IAVI-and-Moderna-Launch-First-in-Africa-Clinical-Trial-of-mRNA-HIV-Vaccine-Development-Program/default.aspx. Published May 18, 2022. Accessed May 18, 2022.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts